The primary efficacy endpoint was change from baseline MADRS score. This brief-phrase review uncovered that, compared to intranasal placebo as well as oral antidepressant, intranasal esketamine in conjunction with an oral antidepressant substantially enhanced depressive signs and symptoms immediately after 4 months by a imply difference of 4 points around https://timocil034lmm8.wikicommunications.com/user